NCT02118740

Brief Summary

This is a observational study in which healthy found volunteers are recruited to donate 50 ml of bone marrow aspirate to enable preclinical studies to obtain proof of concept and safety of a bone marrow derived stem cell preparation named AMARCELL. The prepared AMARCELL is only for animal studies and after completion of the preclinical program, the intention of AMARCELL is to treat humans with a traumatic Spinal cord injury.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2015

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 18, 2014

Completed
1 month until next milestone

First Posted

Study publicly available on registry

April 21, 2014

Completed
1.1 years until next milestone

Study Start

First participant enrolled

June 1, 2015

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2017

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2018

Completed
Last Updated

January 30, 2017

Status Verified

January 1, 2017

Enrollment Period

2.6 years

First QC Date

March 18, 2014

Last Update Submit

January 27, 2017

Conditions

Keywords

Autologous Stem CellsSpinal Cord InjuryPreclinical

Outcome Measures

Primary Outcomes (1)

  • Number of mononuclear cells include hematopoietic stem and progenitor cells in AMARCELL

    Important is to have more than 2 million mononuclear cells (MNCs) include hematopoietic stem and progenitor cells in the end product AMARCELL

    3 days

Secondary Outcomes (1)

  • Absence of contamination with infectious agents especially bacteria and pseudomonas

    3 days

Eligibility Criteria

Age20 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Young healthy volunteers

You may qualify if:

  • Men in the age range of 21-30 years and/or women in the age range of 21-30 years and taking birth control medication to prevent pregnancy
  • Written informed consent
  • Healthy as concluded by the answers given to questions in a short health questionnaire

You may not qualify if:

  • Pregnancy or lactation period
  • Volunteers who are unable to comply with the rules of this project. Important is if the volunteer can not follow the schedule of the appointments.
  • Abuse of alcohol, medicines or illicit drugs.
  • Legally protected people

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

MUMC

Maastricht, Limburg, 6202 AZ, Netherlands

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

A stem cell specimen will be retained to enable verification in the future

MeSH Terms

Conditions

Spinal Cord Injuries

Condition Hierarchy (Ancestors)

Spinal Cord DiseasesCentral Nervous System DiseasesNervous System DiseasesTrauma, Nervous SystemWounds and Injuries

Study Officials

  • Harry Steinbusch, Prof.dr.

    University Maastricht

    STUDY DIRECTOR
  • Gerard Bos, Prof.dr.

    Maastricht University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Johannes de Munter, MD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Target Duration
1 Week
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 18, 2014

First Posted

April 21, 2014

Study Start

June 1, 2015

Primary Completion

December 30, 2017

Study Completion

April 30, 2018

Last Updated

January 30, 2017

Record last verified: 2017-01

Data Sharing

IPD Sharing
Will share

The bone marrow characteristics shall be published as part of the preclinical studies and in particular as a request of the METC

Locations